Abstract
OBJECTIVES: To analyze how the increased frequency of meetings held by the Antimicrobial Stewardship Program (PROA) groupduring which non-mandatory, supportive prescription audits were conductedimpacted antimicrobial use, using hospital antimicrobial consumption-based indicators. To compare these results with those of other centers of similar complexity. MATERIALS AND METHODS: A retrospective cohort study comparing antimicrobial use through hospital antimicrobial consumption-based indicators in 2023 (the first year the PROA team met twice per week) with 2022 (the last year the PROA team met once per week). The comparison with other centers was carried out using the antimicrobial hospital consumption platform of the Pharmaceutical Care Group for Infectious Diseases of the Spanish Society of Hospital Pharmacy. RESULTS: In 2023 compared to 2022, improvements were observed in 7 out of the 13 indicators: overall consumption of systemic antifungals, carbapenem consumption, metronidazole/piperacillin-tazobactam + carbapenem ratio, fosfomycin consumption, anti-MSSA/anti-MRSA agent ratio, amoxicillin-clavulanate/piperacillin-tazobactam ratio, and fluconazole/echinocandin ratio. In 2023, our hospital ranked above the 50th percentile in 7 out of the 13 indicators. CONCLUSIONS: The increased frequency of PROA team meetings may be associated with partial improvements in antimicrobial use, according to hospital antimicrobial consumption-based indicators.